Most small molecule CCR5 inhibitors didn't make it
Post# of 148168
(Total Views: 719)
Posted On: 10/28/2020 9:43:03 AM
Most small molecule CCR5 inhibitors didn't make it past safety... Side effects were serious. The One that did still reported adverse effects. On top of this, it takes days to build levels up to achieve even 40% receptor occupancy, and the half life for some of these is measured in hours.
Nowhere even close to LLMab's safety or effecacy.
Nowhere even close to LLMab's safety or effecacy.
(5)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼